MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, INMB had -$5,640K decrease in cash & cash equivalents over the period. -$5,632K in free cash flow.

Cash Flow Overview

Change in Cash
-$5,640K
Free Cash flow
-$5,632K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-6,472 -34,197
Stock-based compensation
2,984 3,610
Gain on settlement of accounts payable
626 -
Depreciation expense
28 -
Impairment of acquired in-process research and development intangible assets
0 16,514
Research and development tax credit receivable
99 424
Other tax receivable
210 322
Prepaid expenses
-33 174
Accounts payable and accrued liabilities related parties
-159
Other assets
176 491
Accounts payable and accrued liabilities
-170 1,132
Accretion of debt discount
-0
Deferred liabilities
-511 -6
Prepaid expenses related party
-0
Operating lease liabilities
-61 -
Net cash used in operating activities
-5,439 -14,199
Purchase of equipment
193 706
Net cash used in investing activities
-193 -706
Repayments of debt
-0
Net proceeds from sale of common stock and warrants
0 27,544
Exercise of warrants for cash
0 1
Net cash provided by financing activities
0 27,545
Impact on cash from foreign currency translation
-8 -188
Net increase (decrease) in cash and cash equivalents
-5,640 12,452
Cash and cash equivalents at beginning of period
20,922 -
Cash and cash equivalents at end of period
27,734 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Inmune Bio, Inc. (INMB)

Inmune Bio, Inc. (INMB)